SG11202006730SA - Botulinum neurotoxin biohybrid - Google Patents

Botulinum neurotoxin biohybrid

Info

Publication number
SG11202006730SA
SG11202006730SA SG11202006730SA SG11202006730SA SG11202006730SA SG 11202006730S A SG11202006730S A SG 11202006730SA SG 11202006730S A SG11202006730S A SG 11202006730SA SG 11202006730S A SG11202006730S A SG 11202006730SA SG 11202006730S A SG11202006730S A SG 11202006730SA
Authority
SG
Singapore
Prior art keywords
biohybrid
botulinum neurotoxin
neurotoxin
botulinum
neurotoxin biohybrid
Prior art date
Application number
SG11202006730SA
Inventor
Pål Stenmark
Geoffrey Masuyer
Original Assignee
Toxotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toxotech Ab filed Critical Toxotech Ab
Publication of SG11202006730SA publication Critical patent/SG11202006730SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Birds (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202006730SA 2018-02-26 2019-02-21 Botulinum neurotoxin biohybrid SG11202006730SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1850213A SE542539C2 (en) 2018-02-26 2018-02-26 Chimeric botulinum neurotoxin heavy chain binding domain
PCT/EP2019/054310 WO2019162376A1 (en) 2018-02-26 2019-02-21 Botulinum neurotoxin biohybrid

Publications (1)

Publication Number Publication Date
SG11202006730SA true SG11202006730SA (en) 2020-08-28

Family

ID=65576340

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202006730SA SG11202006730SA (en) 2018-02-26 2019-02-21 Botulinum neurotoxin biohybrid

Country Status (15)

Country Link
US (1) US20200407702A1 (en)
EP (1) EP3759124A1 (en)
JP (2) JP7458999B2 (en)
KR (1) KR20200127175A (en)
CN (1) CN111819189A (en)
AU (1) AU2019223130A1 (en)
BR (1) BR112020017323A2 (en)
CA (1) CA3088928A1 (en)
CL (1) CL2020002186A1 (en)
IL (1) IL276930A (en)
MX (1) MX2020008834A (en)
PH (1) PH12020551270A1 (en)
SE (1) SE542539C2 (en)
SG (1) SG11202006730SA (en)
WO (1) WO2019162376A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019158745A1 (en) * 2018-02-16 2019-08-22 Bontana Therapies Gmbh Nucleic acid-based botulinum neurotoxin for therapeutic use
IL272002A (en) * 2020-01-13 2021-07-29 The Israel Institute Of Biological Res Iibr Methods for identifying anti clostridial neurotoxin compounds
EP4093434A2 (en) * 2020-01-21 2022-11-30 Trustees of Dartmouth College Immunologically optimized botulinum toxin light chain variants
CN111675754A (en) * 2020-05-19 2020-09-18 四川一埃科技有限公司 Botulinum toxin protein crystal structure, crystal preparation method and resolution method

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102219837B (en) * 2010-05-20 2013-10-30 中国人民解放军军事医学科学院微生物流行病研究所 Recombinant full-length A-type botulinum toxin mutant vaccine
BR112014029585A2 (en) * 2012-05-30 2017-07-25 Harvard College engineered botulinum neurotoxin
CN107548402B (en) * 2015-03-26 2022-08-19 哈佛大学校长及研究员协会 Engineered botulinum neurotoxin
TW201718627A (en) * 2015-06-11 2017-06-01 梅茲製藥有限兩合公司 Recombinant clostridial neurotoxin, a use thereof, and a method for generating the same, a pharmaceutical composition comprising the same and a precursor corresponding to the same, a nucleic acid sequence encoding the precursor and a method for obtaining
GB201607901D0 (en) * 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
CA3024331A1 (en) 2016-05-16 2017-11-23 President And Fellows Of Harvard College Method for purification and activation of botulinum neurotoxin
SG10201912099TA (en) 2016-06-08 2020-02-27 Childrens Medical Center Engineered botulinum neurotoxins

Also Published As

Publication number Publication date
MX2020008834A (en) 2021-01-08
AU2019223130A1 (en) 2020-09-10
EP3759124A1 (en) 2021-01-06
BR112020017323A2 (en) 2020-12-29
JP2021514674A (en) 2021-06-17
JP2024069606A (en) 2024-05-21
RU2020131317A (en) 2022-03-29
WO2019162376A1 (en) 2019-08-29
IL276930A (en) 2020-10-29
CN111819189A (en) 2020-10-23
CL2020002186A1 (en) 2020-12-28
SE1850213A1 (en) 2019-08-27
CA3088928A1 (en) 2019-08-29
SE542539C2 (en) 2020-06-02
JP7458999B2 (en) 2024-04-01
US20200407702A1 (en) 2020-12-31
KR20200127175A (en) 2020-11-10
PH12020551270A1 (en) 2021-05-31

Similar Documents

Publication Publication Date Title
HK1249119A1 (en) Engineered botulinum neurotoxin
ZA201900341B (en) A novel botulinum neurotoxin and its derivatives
IL263058A (en) Engineered botulinum neurotoxins
SG11202003671VA (en) Non-neuronal snare-cleaving botulinum neurotoxins
IL262575B (en) Chimeric neurotoxins
IL276930A (en) Botulinum neurotoxin biohybrid
GB201621111D0 (en) Neurotoxins
DK3356391T3 (en) PROCEDURE FOR CLEANING CLOSTRIDIAL NEUROTOXIN
DK3882540T3 (en) Køleanordning til containere
IL279880A (en) Engineered phosphopentomutase variant enzymes
EP3615669A4 (en) Botulinum neurotoxins production methods
EP3570816C0 (en) Stable liquid composition comprising botulinum toxin
DK3860777T3 (en) Hydraulisk drivsystem til et stanseapparat
IL267954B (en) Potassium channel modulators
EP3600385A4 (en) Botulinum neurotoxins for treating traumatic injuries
SG11202105592XA (en) Botulinum toxin-stabilizing liquid composition
IL289139A (en) Composition modulating botulinum neurotoxin effect
DK3660218T3 (en) Endeterminal til et autoværn
SG11202100814YA (en) Biohybrid peptidoglycan oligomers
IL263813A (en) Quickchange
AU2024202302A1 (en) Chimeric neurotoxins
GB201917265D0 (en) Bonded neurotoxins
DK3468989T3 (en) Peptider til at inhibere trypsin
KR101881106B9 (en) Pi type attenuator
GB201501783D0 (en) An in-band common control channel